MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions (T2*MRI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00749372|
Recruitment Status : Unknown
Verified November 2010 by Weill Medical College of Cornell University.
Recruitment status was: Recruiting
First Posted : September 9, 2008
Last Update Posted : November 5, 2010
|Condition or disease||Intervention/treatment|
|Myelodysplastic Syndrome (MDS)||Other: T2* Cardiac and Liver MRI|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||T2* Cardiac MRI Screening of Highly Transfused Patients With Myelodysplastic Syndrome|
|Study Start Date :||September 2008|
|Estimated Primary Completion Date :||January 2011|
|Estimated Study Completion Date :||June 2011|
Patients who meet eligibility will be sent for radiographic imaging to include T2* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
Other: T2* Cardiac and Liver MRI
Patients will undergo an MRI of the heart and liver.
- To evaluate the incidence of clinically significant cardiac iron overload in heavily transfused MDS patients using T2* MRI. [ Time Frame: A single T2* MRI will be performed on eligible patients. ]
- Evaluate left ventricular ejection fraction as assessed by T2* MRI. [ Time Frame: A single T2* MRI will be performed on eligible patients. ]
- Evaluate liver iron concentration as assessed by R2* MRI [ Time Frame: A single T2* MRI will be performed on eligible patients. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00749372
|Contact: Tania Curcio, R.N.||212-746-2571|
|United States, New York|
|Weill Medical College of Cornell University||Recruiting|
|New York, New York, United States, 10065|
|Contact: Tania Curcio, R.N. 212-746-2571|
|Principal Investigator: Eric Feldman, M.D.|
|Principal Investigator:||Eric Feldman, M.D.||Weill Medical College of Cornell University|